ARTBIO just dropped a $132 million Series B, and if you’re not paying attention, you’re already behind.
This isn’t just another biotech playing dress-up in clinical trials. This is a company built by radiopharmaceutical legends who invented Xofigo (yes, the one Bayer acquired through Algeta), now reinventing the game with alpha radioligand therapies powered by lead-212. Roy H. Larsen, PhD, and Øyvind Bruland, MD, PhD, don’t dabble, they build category-defining breakthroughs. And with Emanuele Ostuni, PhD, steering as founding CEO, after running cell and gene therapy across Europe for Novartis Oncology, you’re looking at a crew that knows how to turn science fiction into FDA filings.
ARTBIO is one of the fastest-rising teams in biotech, moving from seed to $245 million in less than 26 months. While most startups are still trying to find a logo, these folks are scaling a distributed radiopharma manufacturing model that could fix a century-old problem: how to get life-saving isotopes like ²¹²Pb to patients, safely, on time, and at scale. Forget chasing unicorns. ARTBIO is hand-building a nuclear-powered freight train, and it’s on schedule.
This Series B, co-led by Sofinnova Investments and B Capital, with fresh capital from Qatar Investment Authority and Alexandria Venture Investments, proves it. And let’s not forget the OG believers: F-Prime Capital, Omega Funds, and Third Rock Ventures, all doubling down. Because when you see a Pb212-based platform like AlphaDirect™ delivering 99.9% purity from a benchtop generator, you don’t ask questions. You write checks.
Lead asset B001 just wrapped Phase 0, showing clean safety, strong biodistribution, and an 8-hour effective half-life that actually works with small-molecule carriers. Now rolling into Phase I/II to take on metastatic castration-resistant prostate cancer. Meanwhile, partnerships with 3B Pharmaceuticals and AlphaGen Therapeutics are setting the global board. And with manufacturing alliances across Minnesota, New York, Boston, Berlin, Jintan, and Indiana, this thing is built like a chessmaster’s endgame, three moves ahead and hard to beat.
Philippe Dasse, PharmD is building the tech ops engine, Margaret Yu, MD is leading clinical, and Daniel Rossetto, MSc is running a supply chain with the precision of a Swiss watch powered by reactor-grade isotopes. From Cambridge to Oslo, London to Basel, this company is scaling like it’s got a mission and a map, and now, $132 million more in fuel.
Startups Startup Funding Venture Capital Series B Biotech Biotechnology Bioscience Health Tech Healthcare Deep Tech Technology Innovation Tech Ecosystem Startup Ecosystem
If software engineering peace of mind is what you crave, Vention is your zen.
